Grace Therapeutics, Inc. Research And Development Expense
Grace Therapeutics, Inc. (GRCE) reported Research And Development Expense of CAD 38.37 million for the 12-month period ending 2019-03-31, per its 20-F filed 2019-06-26.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2019-06-26
| Period end | Research And Development Expense 1 month | Research And Development Expense 12 month | Research And Development Expense 13 month |
|---|---|---|---|
| 2019-03-31 | 38.37M CAD 20-F · filed 2019-06-26 | ||
| 2018-03-31 | 15.67M CAD 20-F · filed 2019-06-26 | ||
| 2017-03-31 | 426.00K CAD 20-F · filed 2019-06-26 | 7.65M CAD 20-F · filed 2019-06-26 | |
| 2017-02-28 | 7.23M CAD 20-F · filed 2019-06-26 | ||
| 2016-02-29 | 7.57M CAD 20-F · filed 2018-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |